EA201000829A1 - Вакцина - Google Patents

Вакцина

Info

Publication number
EA201000829A1
EA201000829A1 EA201000829A EA201000829A EA201000829A1 EA 201000829 A1 EA201000829 A1 EA 201000829A1 EA 201000829 A EA201000829 A EA 201000829A EA 201000829 A EA201000829 A EA 201000829A EA 201000829 A1 EA201000829 A1 EA 201000829A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv
gag
immunogenic
vaccine
component
Prior art date
Application number
EA201000829A
Other languages
English (en)
Inventor
Доминик Ингрид Лемуан
София Валерия Анна Понсар
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201000829A1 publication Critical patent/EA201000829A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Компонент для вакцины против ВИЧ или жидкий нефасованный препарат, содержащий: а) иммуногенный слитый белок, содержащий Nef или его иммуногенный(ое) фрагмент или производное и р17 Gag и/или р24 Gag или их иммуногенные фрагменты или производные, причем когда присутствуют оба р17 и р24 Gag, тогда между ними находится по меньшей мере один антиген или иммуногенный фрагмент ВИЧ, и б) стабилизирующий агент, выбранный из группы, содержащей или состоящей из монотиоглицерина, цистеина, N-ацетилцистеина или их смесей. Изобретение также охватывает вакцины против ВИЧ, содержащие указанный компонент для вакцины против ВИЧ или жидкий нефасованный препарат, и применение в лечении/предупреждении ВИЧ.
EA201000829A 2007-12-21 2008-12-18 Вакцина EA201000829A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1576707P 2007-12-21 2007-12-21
US1995108P 2008-01-09 2008-01-09
PCT/EP2008/067945 WO2009080719A1 (en) 2007-12-21 2008-12-18 Vaccine

Publications (1)

Publication Number Publication Date
EA201000829A1 true EA201000829A1 (ru) 2011-06-30

Family

ID=40577907

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000829A EA201000829A1 (ru) 2007-12-21 2008-12-18 Вакцина

Country Status (16)

Country Link
US (2) US20100285051A1 (ru)
EP (1) EP2247307A1 (ru)
JP (2) JP2011506565A (ru)
KR (1) KR20100109555A (ru)
CN (1) CN101951950A (ru)
AU (1) AU2008339984A1 (ru)
BR (1) BRPI0821555A2 (ru)
CA (1) CA2708718A1 (ru)
CO (1) CO6290701A2 (ru)
CR (1) CR11575A (ru)
DO (1) DOP2010000188A (ru)
EA (1) EA201000829A1 (ru)
IL (1) IL206307A0 (ru)
MA (1) MA32018B1 (ru)
WO (1) WO2009080719A1 (ru)
ZA (1) ZA201004303B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
EP2556377B1 (en) 2010-04-08 2017-07-12 University of Pittsburgh - Of the Commonwealth System of Higher Education B-cell antigen presenting cell assay
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2014113634A1 (en) * 2013-01-17 2014-07-24 University Of Kansas Toll-like receptor 2-agonistic lipopeptides, and method of making the same
CN103330935A (zh) * 2013-06-17 2013-10-02 中山大学 果糖作为疫苗佐剂的应用
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
KR20180115276A (ko) 2016-02-22 2018-10-22 베링거잉겔하임베트메디카게엠베하 생체 분자의 고정화 방법
JP2021519596A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ フェリチンタンパク質
WO2019195314A2 (en) * 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
WO2020030572A1 (en) * 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464474A (en) * 1980-07-09 1984-08-07 Connaught Laboratories Limited Non-A, non-B hepatitis assay and vaccine
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AU758604B2 (en) * 1998-07-31 2003-03-27 Intervet International B.V. Attenuated equine herpesvirus
WO2002017956A2 (en) * 2000-08-31 2002-03-07 Chiron Corporation Stabilized fgf formulations containing reducing agents
FR2813756B1 (fr) * 2000-09-11 2003-03-07 Imv Technologies Dilueur pour la conservation de spermatozoides de porcins
CA2453880A1 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CA2477191A1 (en) * 2002-02-04 2003-08-28 Sally Mossman Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
US20030215455A1 (en) * 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
GB0300427D0 (en) * 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
CN1905896A (zh) * 2003-12-05 2007-01-31 贝克顿·迪金森公司 增强皮内隔室中的免疫反应的方法和其中使用的化合物
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity

Also Published As

Publication number Publication date
KR20100109555A (ko) 2010-10-08
CN101951950A (zh) 2011-01-19
EP2247307A1 (en) 2010-11-10
CO6290701A2 (es) 2011-06-20
JP2015007067A (ja) 2015-01-15
ZA201004303B (en) 2011-11-30
DOP2010000188A (es) 2010-10-31
CR11575A (es) 2010-09-29
CA2708718A1 (en) 2009-07-02
AU2008339984A1 (en) 2009-07-02
WO2009080719A1 (en) 2009-07-02
JP2011506565A (ja) 2011-03-03
BRPI0821555A2 (pt) 2015-06-16
US20100285051A1 (en) 2010-11-11
IL206307A0 (en) 2010-12-30
MA32018B1 (fr) 2011-01-03
US20140193481A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
EA201000829A1 (ru) Вакцина
SG155206A1 (en) Vaccine for prevention and treatment of hiv-infection
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
EA200700904A1 (ru) Вакцины против вируса японского энцефалита и вируса западного нила
EA200800033A1 (ru) Композиция (варианты), способ ее получения, резервуар, содержащий указанную композицию, и способ лечения вирусных заболеваний с ее использованием
WO2007030810A3 (en) Multiparameter whole blood monitor and method
PE20060149A1 (es) Formulacion farmaceutica para tratar la infeccion por vih
CY1113288T1 (el) Ανασυνδυασμενοι φορεις που βασιζονται επι του τροποποιημενου ιου αγκυρας (mva) ως αποτρεπτικα και θεραπευτικα εμβολια εναντι aids
EA200901490A1 (ru) Химические соединения
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
EA200001030A1 (ru) Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов
NZ597458A (en) Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
PE20060148A1 (es) Composicion farmaceutica para tratar la infeccion por vih
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
PE20061372A1 (es) Composicion farmaceutica que contiene un vector adenovirus
EA200970586A1 (ru) Антитела к цитомегаловирусу человека (hcmv)
EA201170353A1 (ru) Антитела против гепатита с и их применение
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
WO2008118849A3 (en) Hiv-1 protease inhibitors
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
MX2023003199A (es) Vacuna contra la enfermedad por coronavirus de 2019 (covid-19) basada en el virus de la parainfluenza 5 (piv5).
WO2006071896A3 (en) Epitope-based sars vaccine
EA201270108A1 (ru) Формирование полиспецифического t-клеточного ответа против вич у человека
EP2495252A3 (en) Soluble forms of hendra and nipah virus G glycoprotein
EA200702079A1 (ru) Вакцина